Adjuvant treatment decisions of patients with stage IIB/C and III melanoma in routine clinical practice.

The introduction of modern adjuvant therapies for melanoma has marked a paradigm shift for stage III in 2018 and stage IIB/C in 2022. However, patients' decisions sometimes deviate from the advice of physicians. This retrospective study aimed to evaluate adjuvant treatment decisions, influencing factors, and outcomes for melanoma patients with stage IIB/C and III receiving routine care at the Vivantes Skin Cancer Center, which operates across three locations in Berlin, Germany.